Status: Recruiting
A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
This Phase 1/2, multicenter, open-label, FIH study aims to evaluate the safety, tolerability, PK, and preliminary antitumor activity of CRN09682 in participants with SST2-expressing NENs and other solid tumors. The study includes a Dose Escalation Phase to determine the MTD and DLTs. Following MTD identification, additional participants will be enrolled at the expansion dose to further assess safety, tolerability, PK, and antitumor activity.
Participants needed: 150
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Crinetics Pharmaceuticals Inc.Updated: Jul 1, 2026Locations: 26
Eligibility criteria
Have a histological diagnosis of metastatic or locally advanced inoperable NET,... [+3]
Have tumor progression while undergoing a course of PRRT or within 6 months of c... [+8]